SCHEMBL29366018

SCHEMBL29366018

Cc1nc2ccc(OC(F)(F)F)cc2c(Cl)c1C(=O)N(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 3/20 0.47
RORC P51449 1/20 0.41
PTGFR P43088 2/20 0.39
DHFR P00374 1/20 0.39
DYRK1A Q13627 1/20 0.39
ALDH1A1 P00352 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MCHR1 Q99705 3/20 0.38
HDAC3 O15379 1/20 0.38
APP P05067 1/20 0.38
ACHE P22303 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
SLC6A2 P23975 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29365976 0.78 TP53 (0.46) DHODHDYRK1AACHESLC6A2SLC6A4
SCHEMBL22589503 0.78 TP53 (0.46) DHODHDYRK1AACHESLC6A2SLC6A4
SCHEMBL27498883 0.76 DHODH (0.57) DHODHPTGFRDYRK1AHDAC3APP
SCHEMBL15491289 0.74 DHODH (0.64) DHODHPTGFRDYRK1AALDH1A1HDAC3
SCHEMBL2833192 0.74 PKM (0.47) DHODHDHFRDYRK1AALDH1A1L3MBTL1
SCHEMBL2824236 0.74 DHODH (0.58) DHODHALDH1A1
SCHEMBL2824250 0.73 DHODH (0.57) DHODHALDH1A1
SCHEMBL15491291 0.73 DHODH (0.54) DHODHPTGFRDYRK1AALDH1A1HDAC3
SCHEMBL16400838 0.73 PLA2G2A (0.60) DHODHALDH1A1L3MBTL1
SCHEMBL2823273 0.73 DHODH (0.48) DHODHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486234-B2 PAPD5 inhibitors and methods of use thereof CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-12-02 US disclosed
CN-119798159-A PAPD5 inhibitors and methods of use thereof 儿童医学中心公司 2025-04-11 CN disclosed
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION 2022-09-01 US disclosed
EP-3959197-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-03-02 EP disclosed
CN-113993848-A Inhibitors of PAPD5 and methods of use thereof 儿童医学中心公司 2022-01-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT DHODH 2514/4885RORC 4761/4885PTGFR 3713/4885
US-12486234-B2 PAPD5 inhibitors and methods of use thereof POT1, PARP15, TERT DHODH 2514/4885RORC 4761/4885PTGFR 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.